Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients

The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) is a scale for assessing severity in autoimmune encephalitis. We aimed to validate the CASE score in a Chinese population and evaluate its clinical significance. Patients diagnosed with autoimmune encephalitis were recruited between Jun...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2021-12, Vol.12, p.796965-796965
Main Authors: Zhang, Yingchi, Tu, Ewen, Yao, Chenxiao, Liu, Jia, Lei, Qiang, Lu, Wei
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Asians
Autoimmune Diseases - diagnosis
Autoimmune Diseases - mortality
Autoimmune Diseases - therapy
autoimmune encephalitis
CASE scores
Child
China - epidemiology
Clinical Decision-Making
Decision Support Techniques
Encephalitis - diagnosis
Encephalitis - ethnology
Humans
Immunology
Male
Middle Aged
mRS scores
Predictive Value of Tests
Prognosis
Reproducibility of Results
Severity of Illness Index
Symptom Assessment
validation
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) is a scale for assessing severity in autoimmune encephalitis. We aimed to validate the CASE score in a Chinese population and evaluate its clinical significance. Patients diagnosed with autoimmune encephalitis were recruited between June 2014 and May 2019 from two hospitals. CASE and modified Rankin Scale (mRS) scores were obtained. Data regarding clinical features, treatment, and available information were gathered from the hospital information system. Of the 176 patients with autoimmune encephalitis, 11 died and 14 had tumors. Ten patients received second-line treatment. The CASE scores of patients receiving second-line treatment were significantly higher (median CASE: 15) than in those receiving first-line treatment (median CASE: 8) (p2). Areas under the curve of CASE on whether functional status was poor at 1 year were 0.89 (p
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.796965